Annexon Biosciences, Inc. (ANNX)
Stock Price:
$24.59 USD
-1.64 (-6.25%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
938.06M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-44.83M |
| Shares Out |
38.15M |
| EPS (ttm) |
-1.18 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$24.59 |
| Previous Close |
$26.23 |
| Change ($) |
-1.64 |
| Change (%) |
-6.25% |
| Day's Open |
26.20 |
| Day's Range |
24.36 - 26.97 |
| Day's Volume |
215,822 |
| 52-Week Range |
15.33 - 31.84 |
More Stats
| Market Cap |
938.06M |
| Enterprise Value |
813.30M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
38.15M |
| Float |
25.61M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-1.18 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.19M |
| Short Ratio |
3.73 |
| Short % of Float |
4.65% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
29.47 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-44.83M |
| Free Cash Flow |
n/a |
| Net Cash |
124.76M |
| Net Cash / Share |
3.27 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-32.14% |
| ROE |
-63.39% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$33.00*
(34.20% upside)
Low
33.0
Current: $24.59
High
33.0
Target: 33.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -32.52 | -19.15 |
| Net Income | -37.18 | -18.30 |
| Shares Outstanding | 0.43 | 0.40 |
| Earnings Per Share | -88.30 | -45.89 |
| Operating Cash Flow | -28.36 | -17.19 |
| Capital Expenditures | -0.27 | -0.02 |
| Free Cash Flow | -28.63 | -17.21 |
| Cash & Equivalents | 43.93 | 44.18 |
| Net Cash / Debt | 43.93 | 44.18 |
| Assets | 49.90 | 48.15 |
| Liabilities | 6.37 | 10.27 |
| Book Value | -100 | -64.20 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Annexon Biosciences, Inc. |
| Country |
United States |
| Employees |
30 |
| CEO |
Douglas Love |
Stock Information
| Ticker Symbol |
ANNX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ANNX |
| IPO Date |
July 24, 2020 |
Description
Annexon, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.